Saham · Kesehatan
Perpetual futures Waters Corporation (WAT)
Perpetual futures WAT di 1 bursa kripto – harga perp vs saham, funding rate, open interest, dan tempat trading WATUSDT.
Waters Corporation memproduksi instrumen analitik, termasuk sistem kromatografi cair dan spektrometri massa, serta perangkat analisis termal, reometri dan kalorimetri, dengan perangkat lunak dan layanan untuk laboratorium.
Grafik harga
Gunakan tombol panah kiri dan kanan untuk memeriksa titik pada grafik.
Data perdagangan
Aktivitas pasar perpetual
1/1 pasar langsung
Data perdagangan
Aktivitas pasar perpetual
Kinerja spot
Matriks bursa
1 pasar
Beberapa tautan bursa disponsori. Kami mungkin menerima komisi, dan pengguna yang memenuhi syarat sesekali dapat menerima diskon biaya perdagangan, tanpa biaya tambahan bagi Anda.
| Perdagangkan | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 MEXC | Perdagangkan | WAT/USDT | Diperdagangkan | $491,07 | -13,9% APR -0,013% setiap 8h | +458,6 bps | $0 | $119,1 rb | $62,3 rb | USDT | 20x |
Kelayakan trading
Kualitas eksekusi
Biaya masuk dan kedalaman per bursa untuk $1k–$100k
Kelayakan trading
Kualitas eksekusi
Biaya masuk dan kedalaman per bursa untuk $1k–$100kKedalaman tidak cukup · 0 dari 1 bursa menyerap $10k
Tidak ada data order book terbaru: MEXC
Perkiraan eksekusi taker termasuk biaya aprox. - fill maker tidak dijamin.
Bursa terbaik untuk underlying ini
Likuiditas terbaik
WATSpread terketat
WATVolume tertinggi
WATRiwayat funding
Snapshot bursa tersimpan per pasar
Riwayat funding
Snapshot bursa tersimpan per pasarKatalis berikutnya
Katalis
Katalis berikutnya
Katalis
Tidak ada aktivitas perp yang tidak biasa saat ini.
Data riset
Analis, laporan, dan konteks perusahaan sejenis
Data riset
Analis, laporan, dan konteks perusahaan sejenis
Estimasi
6Peristiwa perusahaan
6Perbandingan perusahaan sejenis
Perp sejenis yang terdaftarKomposisi pendapatan
Tahunan terakhirAnalis
Target hargaRiwayat rating analis
RatingKepemilikan
Institusional · 2026-Q3Aktivitas pasar referensi
WAT-PERPKinerja harga
11Aktivitas orang dalam
TF2026 K3Transaksi orang dalam
25Eksekutif Waters Conly D Steven mengajukan Form 3 awal pada 6 November 2026, mengungkap 10 kepemilikan per 29 Oktober 2026: 6.030 saham biasa, 8 hak apresiasi saham pada $411,85-$464,50 dan satu opsi pada $319,44. Semua baris mencatat 0 saham ditransaksikan; tidak ada pembelian atau penjualan yang dilaporkan.
Direktur Waters Corporation Heather Knight menerima hibah 57 saham biasa (kode A-Award, bukan pembelian) pada 30/09/2026, sehingga kepemilikannya menjadi 1.338 saham.
Direktur Waters Corporation Jiang Wei menerima 57 saham biasa melalui pemberian (kode A), yaitu hibah bukan pembelian di pasar terbuka; setelahnya ia memiliki 3.630 saham.
Pejabat Waters Corporation Wu Tong mengajukan Formulir 3 pada 2026-08-31 tanpa saham atau transaksi; satu-satunya baris menunjukkan 0 saham biasa pada $0.00.
Direktur Waters Christopher A. Kuebler mengeksekusi opsi atas 3.626 saham biasa pada $136,43 dan menjual 3.626 saham yang sama pada $397,94, menyisakan 17.808 saham dimiliki.
Direktur Waters Corporation Heather Knight menerima pemberian 63 saham biasa pada 30/06/2026 seharga $0,00, yaitu kompensasi (kode A) bukan pembelian di pasar terbuka; setelahnya ia memiliki 1.281 saham.
Direktur Jiang Wei menerima penghargaan 67 saham biasa Waters Corporation pada 30 Juni 2026 dengan harga $0,00 per saham, sehingga kepemilikannya menjadi 3.573 saham.
Eksekutif Waters Robert L. Carpio III melaporkan pelepasan 189 saham biasa pada harga US$369,18 per saham pada 24/06/2026, kode F-InKind untuk pemotongan pajak, dengan 3.426 saham tersisa dimiliki.
CFO Waters Corporation (WAT) Chaubal Amol mengalami pemotongan 239 saham biasa untuk pajak pada $352,21 per saham pada 12.05.2026, menyisakan 7.623 saham dimiliki.
Eksekutif Waters Bennett Jianqing melepas 302 saham biasa pada $304,09 per saham tanggal 06/04/2026 dengan kode F (pemotongan pajak), menyisakan 6.532 saham.
Direktur Waters Corp Jiang Wei menerima hibah 64 saham biasa seharga $0,00 dan kini memiliki 3.505 saham. Hibah dilaporkan dalam Formulir 4 yang diajukan pada 02/04/2026.
Direktur Waters Corporation Knight Heather menerima pemberian 68 saham biasa pada 31/03/2026, sehingga kepemilikannya menjadi 1.218 saham.
Direktur Jiang Wei membeli 500 saham biasa Waters Corporation di pasar terbuka pada 16/03/2026 seharga US$289,46 per saham (P-Purchase), sehingga kepemilikannya menjadi 3.441 saham. Form 4 diajukan pada 18/03/2026.
Direktur Richard H. Fearon membeli 1.000 saham Waters Corporation di pasar terbuka pada 6 Maret 2026 seharga $306,34 per saham, sehingga kepemilikannya menjadi 3.302 saham.
Pengajuan
30 · Pengajuan SEC terbaruEksekutif Waters Conly D Steven mengajukan Form 3 awal pada 6 November 2026, mengungkap 10 kepemilikan per 29 Oktober 2026: 6.030 saham biasa, 8 hak apresiasi saham pada $411,85-$464,50 dan satu opsi pada $319,44. Semua baris mencatat 0 saham ditransaksikan; tidak ada pembelian atau penjualan yang dilaporkan.
Direktur Waters Corporation Heather Knight menerima hibah 57 saham biasa (kode A-Award, bukan pembelian) pada 30/09/2026, sehingga kepemilikannya menjadi 1.338 saham.
Direktur Waters Corporation Jiang Wei menerima 57 saham biasa melalui pemberian (kode A), yaitu hibah bukan pembelian di pasar terbuka; setelahnya ia memiliki 3.630 saham.
Pejabat Waters Corporation Wu Tong mengajukan Formulir 3 pada 2026-08-31 tanpa saham atau transaksi; satu-satunya baris menunjukkan 0 saham biasa pada $0.00.
Direktur Waters Christopher A. Kuebler mengeksekusi opsi atas 3.626 saham biasa pada $136,43 dan menjual 3.626 saham yang sama pada $397,94, menyisakan 17.808 saham dimiliki.
Direktur Waters Corporation Heather Knight menerima pemberian 63 saham biasa pada 30/06/2026 seharga $0,00, yaitu kompensasi (kode A) bukan pembelian di pasar terbuka; setelahnya ia memiliki 1.281 saham.
Direktur Jiang Wei menerima penghargaan 67 saham biasa Waters Corporation pada 30 Juni 2026 dengan harga $0,00 per saham, sehingga kepemilikannya menjadi 3.573 saham.
Eksekutif Waters Robert L. Carpio III melaporkan pelepasan 189 saham biasa pada harga US$369,18 per saham pada 24/06/2026, kode F-InKind untuk pemotongan pajak, dengan 3.426 saham tersisa dimiliki.
CFO Waters Corporation (WAT) Chaubal Amol mengalami pemotongan 239 saham biasa untuk pajak pada $352,21 per saham pada 12.05.2026, menyisakan 7.623 saham dimiliki.
Eksekutif Waters Bennett Jianqing melepas 302 saham biasa pada $304,09 per saham tanggal 06/04/2026 dengan kode F (pemotongan pajak), menyisakan 6.532 saham.
Direktur Waters Corp Jiang Wei menerima hibah 64 saham biasa seharga $0,00 dan kini memiliki 3.505 saham. Hibah dilaporkan dalam Formulir 4 yang diajukan pada 02/04/2026.
Direktur Waters Corporation Knight Heather menerima pemberian 68 saham biasa pada 31/03/2026, sehingga kepemilikannya menjadi 1.218 saham.
Transkrip
Earnings callTF2026 K32026-11-03
Earnings call
Ringkasan AI
positiveWaters reported Q3 FY2026 total as-reported revenue of $1.767 billion, comprising $871 million of organic revenue (up 9% as reported, 10% constant currency) and $896 million from Waters Bioscience and Waters Diagnostic Solutions (up 1% reported). Adjusted EPS rose 21% to $4.10, $0.05 above the high end of guidance, and orders outpaced sales by approximately $20 million. Management raised full-year 2026 revenue guidance by $43 million at the midpoint and lifted adjusted EPS guidance to $14.60-$14.70. For Q4, guidance calls for organic constant currency growth of 7%-9%, roughly 9%-11% on a days-adjusted basis, and approximately 10% reported growth for acquired businesses. For 2027, Waters framed a starting assumption of high single-digit growth for legacy Waters, mid-single digits for legacy BD and mid-single-digit-plus combined organic growth, with 100 basis points of adjusted operating margin expansion to 29.2% and low-teens adjusted EPS growth, with mid-teens as the upside case.
Poin utama
- Organic revenue grew 10% constant currency, at the high end of guidance, with orders exceeding sales by about $20 million.
- Analytical Sciences grew 9% constant currency, led by chemistry up 12%, instruments up 10% and service up 8%.
- Biosciences grew 2% reported as flow reagents rose 8% and China returned to positive growth for the first time in 10 quarters.
- Advanced Diagnostics grew 2% reported; Diagnostic Solutions was flat as planned, while the organic clinical business grew 18% constant currency.
- Management cited pharma reshoring, AI-driven demand, China improvement and semiconductor/data center testing as incremental growth vectors not included in the 2027 starting framework.
Sorotan keuangan
- Q3 total as-reported revenue was $1.767 billion; organic revenue was $871 million and Biosciences/Diagnostic Solutions contributed $896 million.
- Adjusted EPS grew 21% to $4.10; GAAP diluted EPS was $0.82.
- Adjusted gross margin was 55.8% and adjusted operating margin was 30.1%.
- Free cash flow was $68 million after approximately $81 million of integration-related costs and $240 million of timing items.
Proyeksi
- FY2026 organic constant currency growth guidance raised 140 basis points at the midpoint to 9.1%-9.7%; total 2026 reported revenue expected at approximately $6.479-$6.497 billion, a $43 million raise at the midpoint.
- FY2026 adjusted EPS guidance raised to $14.60-$14.70, representing 11%-12% year-over-year growth and 13%-14% in constant currency; adjusted EBIT margin of 28.2%, net interest expense of $196 million and a 15.4% tax rate.
- Q4 2026 guidance: organic constant currency growth of 7%-9%, total reported revenue of $1.801-$1.819 billion and adjusted EPS of $4.58-$4.68.
- Initial 2027 framework: mid-single-digit-plus combined organic growth (legacy Waters high single digits, legacy BD mid-single digits), adjusted operating margin of 29.2% and low-teens adjusted EPS growth, with mid-teens as the upside case.
Tema tanya jawab
- Levers that could move 2027 growth above the mid-single-digit-plus starting point, including pricing, new products, reshoring, AI and China.
- Whether AI-driven demand can be quantified as incremental revenue, with management saying it is too early to size.
- 2027 margin bridge including the first six weeks of BD ownership and cost synergies versus reinvestment.
- Free cash flow trajectory and the phasing of integration costs, BD receivables and inventory reduction.
Risiko
- Q4 guidance assumes no budget flush and reflects four fewer selling days in the quarter.
- China diagnostics faced DRG headwinds that diluted segment growth by approximately 200 basis points before annualizing into the baseline in Q4.
- Free cash flow in 2026 was affected by integration and SAP-related costs and about $240 million of timing items expected to normalize in 2027.
TF2026 K22026-08-04
Earnings call
Ringkasan AI
positiveWaters reported Q2 2026 total as-reported revenue of $1.645 billion, comprising $828 million of organic revenue and $817 million from the acquired Biosciences and Diagnostic Solutions businesses. Organic revenue grew 7% as reported and 9% in constant currency, about 100 basis points above the high end of the currency guidance range, with orders outpacing sales. Acquired businesses grew 4% on a reported basis versus the prior year comparable period and exceeded guidance by $15 million. Adjusted EPS was $3.05, at the high end of guidance, while GAAP diluted loss per share was $1.39 due to acquisition-related purchase accounting charges. Management raised every component of full-year 2026 guidance and cited completed cost actions of $75 million in 2026 and approximately $200 million of expected run-rate savings.
Poin utama
- Organic revenue grew 9% in constant currency, with instruments up 8%, chemistry up 10% and service up 9% in Analytical Sciences.
- Analytical Sciences pharma grew 11% and academic/government grew 11%; industrial grew 1% as chemical analysis softness offset double-digit PFAS growth.
- Biosciences grew 3% as reported, improving 400 basis points from Q1; excluding China it grew 5%, and Flow Clinical grew 8% with mid-teens growth outside China.
- Advanced Diagnostics grew 7% as reported, with Diagnostic Solutions up 5% and the Clinical Business Unit up 15% as reported and 14% constant currency.
- The 180-day plan is delivering: 90 basis points of net price realization in acquired businesses in Q2, targeting 150 basis points, alongside China export license improvements and reagent rental compliance remediation.
Sorotan keuangan
- Total company as-reported revenue was $1.645 billion; organic revenue was $828 million, up 7% as reported and 9% in constant currency.
- Biosciences and Diagnostic Solutions revenue was $817 million, up 4% reported versus the prior year comparable period, led by 6% growth outside China.
- Total company adjusted gross margin was 54% and adjusted operating margin was 25%; tax rate was 15.6% and net interest expense was $55 million.
- Free cash flow was $202 million after approximately $21 million in severance payments and $27 million of integration cost payments; net cash settlement due to BD was $157 million at end of June.
Proyeksi
- Full-year 2026 organic constant currency revenue growth raised to 7% to 9%, with FX a headwind of about 60 basis points; organic reported revenue of $3.37 billion to $3.431 billion.
- Biosciences and Diagnostic Solutions 2026 reported revenue expected at approximately $3.045 billion, raised $10 million net (underlying improvement of $25 million offset by $15 million FX); total 2026 reported revenue of approximately $6.415 billion to $6.476 billion.
- Full-year adjusted EPS guidance of $14.45 to $14.65, representing 10% to 12% growth as reported and 12% to 14% in constant currency; adjusted EBIT margin of 28.2%.
- Q3 2026 guidance: organic constant currency growth of 8% to 10%, organic reported revenue of $850 million to $867 million, acquired business revenue of approximately $895 million, total revenue of $1.745 billion to $1.762 billion, and adjusted EPS of $3.95 to $4.05.
Tema tanya jawab
- Sustainability of the acquired-business acceleration and how to reconcile Q3/Q4 growth math, including BD fiscal-year trade inventory dynamics and the expectation to exit 2026 at 6% or better.
- Pricing execution in the acquired businesses, including deal desk implementation, the path from 90 basis points to 150 basis points, and reagent rental contract compliance.
- Flow cytometry turnaround: China localization timing, export license approvals, leadership change, and the FACSDiscover A7 launch set for September 15.
- Cost actions and margin trajectory, including the $50 million Q4 cost benefit as a starting point for 2027 and the 100-basis-point annual margin expansion outlook.
Risiko
- Foreign exchange is a headwind: about 150 basis points adverse to Q2 organic revenue and roughly $0.25 of EPS absorbed by a stronger U.S. dollar, limiting the full-year guidance raise to $0.05.
- China remains a drag in diagnostics and Flow Clinical: China declined 13% in microbiology and 20% in Flow Clinical due to DRG constraints and lack of localized product portfolio.
- Pharma guidance for Q4 implies about 4% constant currency organic growth at the midpoint, below recent seasonal patterns, with approximately 3 fewer working days translating to a 1% to 1.5% headwind.
Berita perusahaan
Reuters, WSJ, Bloomberg, dan FT lebih dulu, sejauh disediakan penyedia berita kami; penerbit lain di filter kedua. Judul tertaut ke penerbit.Tidak ada artikel Reuters, WSJ, Bloomberg, atau FT tentang perusahaan ini di feed kami.
Data perusahaan
Intelijen perusahaan
Diperbarui: 10 Nov 2026, 12.15 UTC
Data perusahaan
Intelijen perusahaan
Profil perusahaan
- Sektor
- Healthcare
- Industri
- Medical - Diagnostics & Research
- Direktur utama
- Udit Batra
- Karyawan
- 15.000
- Tanggal IPO
- 17 Nov 1995
- Negara
- US
- Bursa
- New York Stock Exchange
Faktor peringkat
- Imbal hasil ekuitasi
- 2
- Imbal hasil aseti
- 3
- Utang terhadap ekuitasi
- 2
- Harga terhadap labai
- 1
- Harga terhadap nilai bukui
- 3
Rilis pers perusahaan
Pengungkapan Kongres
Senat
Dewan Perwakilan
Riwayat kapitalisasi pasar
Pemegang dana terbesar
| Dana | Bobot | Saham dimiliki |
|---|---|---|
| VTI | 0,06% | 3,1 jt |
| VOO | 0,07% | 2,6 jt |
| VO | 0,43% | 2,1 jt |
| IVV | 0,07% | 1,3 jt |
| XAW.TO | 0,04% | 1,3 jt |
| 1657.T | 0,05% | 1,3 jt |
| FXAIX | 0,07% | 1,2 jt |
| SPY | 0,07% | 1,2 jt |
| VOT | 1,02% | 771,3 rb |
| VUG | 0,08% | 754,9 rb |
| XLV | 0,67% | 726,8 rb |
| VVORX | 2,45% | 539,6 rb |
Rekam jejak analis
Bagaimana kinerja analis yang meliput WAT: rekomendasi, akurasi target harga, dan reaksi terukur setelah rekomendasi mereka.
| 12 bulan | 3 tahun | |
|---|---|---|
| Rekomendasi | 106 | 248 |
| Analis | 30 | 38 |
| Beli / tahan / jual | 64 / 42 / 0 | 110 / 129 / 9 |
| Naik / turun / inisiasi | 6 / 0 / 10 | 14 / 2 / 15 |
| Target harga tercapai / meleset | 82 / 17 (83%) | 216 / 18 (92%) |
| Rata-rata imbal hasil setelah rekomendasi (TipRanks) | +13,0% | +23,7% |
| Rekomendasi terbaik / terburuk | +44,5% / -11,1% | +107,3% / -31,9% |
Setelah rekomendasi beli pada saham ini: pergerakan median 21 hari +2,1% vs S&P 500 +0,7% (n = 97)
Paling akurat untuk saham ini
Bagian target harga analis untuk saham ini yang dicapai harga dalam 12 bulan (pengukuran kami selama 3 tahun terakhir, minimal 8 target). Ini menggambarkan rekomendasi masa lalu, bukan peluang rekomendasi saat ini.
- Luke SergottBarclays67% tingkat keberhasilan pada saham ini · 9 target diukurBelitarget US$5304 Nov 2026
- Tycho PetersonJefferies56% tingkat keberhasilan pada saham ini · 9 target diukurBelitarget US$47010 Feb 2026
Rekomendasi terbaru
| Tanggal | Analis | Rekomendasi | Target | |
|---|---|---|---|---|
| 4 Nov 2026 | Avantika DhabariaBank of America Securities | TahanDipertahankan | – | artikel ↗ |
| 4 Nov 2026 | David WestenbergPiper Sandler | BeliDipertahankan | US$530 | artikel ↗ |
| 4 Nov 2026 | Daniel BrennanTD Cowen | BeliDipertahankan | US$530 | artikel ↗ |
| 4 Nov 2026 | Joanne WuenschCiti | BeliDipertahankan | US$536 | artikel ↗ |
| 3 Nov 2026 | Dan LeonardRBC Capital | BeliDipertahankan | US$525 | artikel ↗ |
Data TipRanks · dihitung 10 Nov 2026 · 106 rekomendasi
Pertanyaan yang sering diajukan
Di mana saya dapat memperdagangkan perpetual futures WAT?
Perpetual futures Waters Corporation (WAT) diperdagangkan di 1 bursa kripto, termasuk MEXC. PerpEquities membandingkannya berdasarkan harga langsung, funding rate, open interest, dan likuiditas.
Bisakah saya memperdagangkan WAT sepanjang waktu?
Ya. Berbeda dengan saham underlying-nya, perpetual WAT diperdagangkan 24/7 — termasuk akhir pekan dan di luar jam pasar reguler.
Berapa funding rate pada perpetual WAT?
Saat ini funding rate perp WAT adalah -13,9% per tahun (median bursa), berkisar dari -13,9% hingga -13,9% di 1 bursa. Positif berarti long membayar short. PerpEquities menampilkan rate langsung dan riwayatnya untuk setiap bursa.
Bagaimana harga perp WAT dibandingkan saham Waters Corporation?
Harga mark median perp WAT adalah $491,1 versus harga referensi saham $491,1, basis 0,0%. Perp mengikuti saham lewat harga indeks; selisih melebar saat funding atau likuiditas antar bursa berbeda.
Apa itu perpetual future WAT?
Perpetual WAT adalah derivatif yang melacak harga Waters Corporation tanpa tanggal kedaluwarsa. Ini memungkinkan Anda mengambil eksposur long atau short terhadap Waters Corporation di bursa kripto, sepanjang waktu.
Apa itu perpetual WATUSDT?
WATUSDT adalah simbol yang dipakai kebanyakan bursa kripto untuk perpetual Waters Corporation yang diselesaikan dalam USDT (Tether). Ia mengikuti harga saham WAT lewat indeks, diperdagangkan 24/7 dengan leverage, dan tidak pernah kedaluwarsa.
Sematkan aset ini
<a href="https://perpequities.com/id/stocks/wat-perp"><img src="https://perpequities.com/badge/wat-perp.svg" width="240" height="64" alt="WAT perpetuals · perpequities.com" loading="lazy"></a>